Establishment of the 2nd WHO IS for anti-SARS-CoV-2

Report Download the Report Enquiries Connect with our team of dedicated...

Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant). Article Open the...

Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies,today announced new results on the efficacy of Atriva’s lead candidate zapnometinib against coronaviruses. Press Release Open the Press Release...

Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus

Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its PARP inhibitor, stenoparib, against Coronavirus variant B.1.1.7 (British variant). The Pathogen and...

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Article Open the article here Enquiries Connect with our team of dedicated...

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

Peer Reviewed /PUBMED article Article Open the article here Enquiries Connect with our team of dedicated...